Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review updated data from trial evaluating CD47-blocker evorpacept in HER2-positive gastric cancer SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 ...

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies ...

Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review updated data from trial evaluating CD47-blocker evorpacept in HER2-positive gastric cancer The ASPEN-06 data will be featured in an oral ...

Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review updated data from trial evaluating CD47-blocker evorpacept in HER2-positive gastric cancer SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 ...